



Accelerating Antibodies and Biologics to the Clinic

Andrew Satz, CEO
asatz@evqlv.com
www.evqlv.com

Problem

Antibiotic resistance is one of the most challenging global public health threats of our time. As antibiotics become ineffective, other solutions need to come to the forefront.

Solution

EVQLV can support the national efforts by *accelerating the speed of biologic therapies to clinic* by reducing failure rates.

Time
to IND


5 yrs



1 yr

HOW OUR TECHNOLOGY WORKS

EVQLV's technology works for any antibody format:
mAb, scFv, sdAb, Fab, and more



Goal 4: Accelerate Basic and Applied Research and Development for New Antibiotics, Other Therapeutics, and Vaccines

EVQLV's tech can develop antibodies as promising new alternative to antibiotics:

- Expedite monoclonal antibody discovery
- Antibodies as both prophylactic and therapeutic
- Identify target epitopes, optimize existing antibodies, or generate novel antibodies



Goal 3: Advance Development and Use of Rapid and Innovative Diagnostic Tests for Identification and Characterization of Resistant Bacteria

EVQLV's tech can develop rapid diagnostic tests to identify AMR pathogens and resistance proteins:

- Expedite diagnostic test development using antibodies
- Identify epitopes, optimize current diagnostic tests, or develop new diagnostic tests
- Develop companion diagnostics while developing therapies

